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Abstract: Background: High levels of proprotein convertase subtilisin/kexin 9 (PCSK9) is predictive
of cardiovascular events (CVEs) in atrial fibrillation (AF). We hypothesized that PCSK9 may
directly induce platelet activation (PA). Methods: We measured platelet aggregation, recruitment,
Thromboxane B2 (TxB2) formation and soluble P-selectin levels as markers of PA and soluble
Nox2-derived peptide (sNox2-dp), H2O2, isoprostanes and oxidized Low-Density-Lipoprotein
(oxLDL) to analyze oxidative stress (OS) in 88 patients having PCSK9 values < (n = 44) or > (n = 44)
1.2 ng/mL, balanced for age, sex and cardiovascular risk factors. Furthermore, we investigated if
normal (n = 5) platelets incubated with PCSK9 (1.0–2.0 ng/mL) alone or with LDL (50µg/mL) displayed
changes of PA, OS and down-stream signaling. Results: PA and OS markers were significantly higher
in patients with PCSK9 levels > 1.2 ng/mL compared to those with values < 1.2 ng/mL (p < 0.001).
Levels of PCSK9 significantly correlated with markers of PA and OS. Platelets incubation with PCSK9
increased PA, OS and p38, p47 and Phospholipase A2 (PLA2) phosphorylation. These changes were
amplified by adding LDL and blunted by CD36 or Nox2 inhibitors. Co-immunoprecipitation analysis
revealed an immune complex of PCSK9 with CD36. Conclusions: We provide the first evidence that
PCSK9, at concentration found in the circulation of AF patients, directly interacts with platelets via
CD36 receptor and activating Nox2: this effect is amplified in presence of LDL.
Keywords: PCSK9; ROS; oxidative stress; platelets; CD36
1. Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is principally present in the liver, where it is
able to modulate Low-Density-Lipoprotein (LDL) cholesterol uptake acting on its LDL receptor (LDL-R).
The gain of function variants of PCSK9 gene is associated with increased levels of circulating LDL
cholesterol, and a higher risk of cardiovascular events (CVE) [1]. Recent evidence showed that PCSK9
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possesses pro-atherogenic functions independently from its regulatory effect on plasma lipid levels.
Thus, PCSK9 is highly expressed in vascular smooth muscle cells, in human atherosclerotic plaques
and its expression is regulated by several pro-atherogenic mediators, such as tumor necrosis factor α
(TNF-α), reactive oxygen species (ROS) via NADPH oxidase activation, and damaged mitochondrial
DNA [2,3].
A recent prospective study investigated PCSK9 levels in atrial fibrillation (AF) patients and revealed
that high plasma levels of PCSK9 were significantly associated with urinary 11-dehydro-Thromboxane
B2 (11-dh-TxB2), a marker of systemic COX1 activation, suggesting an interplay between PCSK9
and platelet activation [4]. Accordingly, PCSK9 was associated with increased platelet aggregation
in patients with acute coronary syndrome [5] and treatment with anti-PCSK9 mAb was found to
modulate platelet reactivity [6]. The direct involvement of PCSK9 in platelet activation (PA) was
confirmed by PCSK9-/- animal models of mice that presented reduced FeCl3 injury-induced carotid
artery thrombosis [7,8]. Furthermore, human recombinant PCSK9 (hrPCSK9), significantly enhanced
PA but the mechanism was not fully explored [8]. Among the mechanisms involved in PA, ROS and
eventually oxidized LDL (ox-LDL) play an important role via triggering the intra-cellular signaling
of platelet activation [9]. As inhibition of PCSK9 is associated with impaired production of ox-LDL,
it would be possible to postulate that ox-LDL down-regulation might be responsible for PCSK9-induced
PA [10].
Based on this hypothesis, aim of the study was to evaluate if PCSK9, in the range of concentration
achievable in human circulation, may influence PA.
In particular, to explore this issue, we measured bio-markers of PA and OS in AF patients with
PCSK9 values < or > to 1.2 ng/mL. Furthermore, to substantiate that PCSK9 could be biologically active
on platelet activation, we performed in vitro studies to assess (i) the interplay between PCSK9 and
platelet activation, and (ii) oxidative stress, and (iii) to investigate the molecular mechanism involved.
2. Materials and Methods
We performed a cross-sectional study including 88 out of 1135 non-valvular AF patients included
in the ATHERO-AF cohort. Patients were balanced for sex, age and cardiovascular risk factors and
clinical characteristics are reported in Table 1.
Table 1. Characteristics of study population.
Total (n = 88) Below MedianPCSK9 (n = 44)
Above Median
PCSK9 (n = 44) p-Value
Age (years) 73.6 ± 7.7 74.1 ± 8.9 72.8 ± 6.9 0.424
Female sex (%) 48.9 43.2 54.5 0.394
Arterial hypertension (%) 88.6 93.2 84.1 0.314
Diabetes mellitus (%) 18.2 15.9 20.5 0.783
Heart failure (%) 14.8 15.9 13.6 0.764
Prior cerebrovascular events (%) 12.6 15.9 9.3 0.521
Prior cardiac events (%) 22.7 25.0 20.5 0.800
Antiplatelet therapy (%) 00.0
Statins (%) 42.0 47.7 36.4 0.388
Proton pomp inhibitors (%) 43.0 38.6 47.6 0.514
CHA2DS2-VASc score 3.46 ± 1.42 3.64 ± 1.50 3.34 ± 1.40 0.341
Patients were recruited from the Athero-thrombosis Centre of the Department of Clinical, Internal
Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza-University of Rome, for monitoring
and management of antithrombotic therapies. All patients were treated with vitamin K antagonists
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and none of patients were on treatment with antiplatelet drugs. All patients provided written informed
consent at baseline. Ex vivo platelet aggregation and recruitment were performed using citrated blood
samples, which were taken and treated as above reported while for marker of platelet activation and
oxidative stress analysis, the blood was collected in tube without anticoagulant and centrifuged at
300 g for 10 min at room temperature (RT).
The study protocol was approved by the local ethical board of Sapienza-University of Rome
(ethical protocol code is 1306/2007) and was conducted according to principles of the Declaration
of Helsinki.
2.1. Platelet Preparation
Blood samples adding with citrated (3.8%, 1/10 (v: v) were taken between 8 and 9 am from healthy
subjects (HS), (n = 5, males 3, females 2, age 38.8 ± 7.0 years) in fasting conditions. After all subjects
gave written informed consent, they were included in the study. The study protocol was approved by
the local ethical board of Sapienza University of Rome and was conducted according to the principles
of the Declaration of Helsinki.
Blood was centrifuged for 15 min at 180 g at RT and the supernatant obtained was separated
(2 × 105 platelets/µL) and represents platelet-rich plasma (PRP). To exclude leukocyte contamination,
only the top 75% of the PRP was picked. Washed platelets (wPLT) were isolated from PRP by
consecutive centrifugation steps (10 min at 300× g at RT) and resuspended in Tyrode’s buffer (137 mM
NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 1.8 mM CaCl2, 20 mM HEPES, 0.35% w/v bovine serum albumin
(BSA), and 5.6 mM glucose, pH 7.35; Sigma Aldrich, St. Louis MO, USA). To prevent platelet activation,
we added prostaglandin E1 (PGE1,1 µM).
2.2. Platelet Aggregation and Recruitment
For ex vivo study, platelet aggregation was induced with collagen (2 µg/mL, Mascia Brunelli, Italy,
EU) and was measured for 8 min, subsequently platelet recruitment (PR), that is an vitro method to
evaluate thrombus formation, was performed as previously described [11]. Briefly, after 8 min from the
aggregation induction with collagen, an equal quantity of untreated PRP was added to each sample that
increased the density of the solution; this event produced a reduction in light transmission. Therefore,
the aggregation of the freshly added platelet portion in the presence of an existing aggregate was
measured for 5 min and expressed as a percentage of the aggregation (percentage of light transmission)
that had initially been reached [11]. Instead, for in vitro study, PRP was stimulated with a subthreshold
concentration (STC, 0.25 µg/mL), the concentration of agonists was defined as the highest concentration
that elicited < 20% platelet aggregation of collagen as a primer. Before activation, samples were
pre-incubated (20 min at 37 ◦C) with Nox2 inhibitor, that specifically inhibits interactions between
Nox2 and p47phox (Nox2ds-tat, 10 µM; Anaspec, Fremont, CA, USA); or anti-PCSK9 (5 µM; Abcam,
Cambridge, UK); anti-CD36 and anti-LOX1 (5 µM; Cayman, Ann Arbor, MI, USA; Abcam, Cambridge,
UK, respectively), that are two receptors on the platelet surface that binds and internalizes oxLDL;
or an inhibitor of cytosolic phospholipase A2 (AACOCF3, 1 µM; Tocris, Bristol, UK); or p38 inhibitor
(SB202190, 5 µmol/L; Santa Cruz Biotechnology, Dallas, TX, USA). After incubation, platelets were
treated with PCSK, in the range of concentration achievable in circulation of AF patients, (1–2 ng/mL;
Selleckchem S302, Houston, TX, USA) for 5 min before of activation. Finally, samples were centrifuged
for 3 min at 3000 rpm and supernatants and pellets were stored at –80 ◦C for analysis of H2O2, sNox2-dp,
isoprostanes, TXB2, ox-LDL production and p38, p47 and PLA2 phosphorylation, as reported below.
PA was performed on PRP with Platelet Aggregation Profile–8E (Bio/Data Horsham, PA, USA), using
siliconized glass cuvettes in constant stirring condition, using Born method [12]. Furthermore, to assess
if PCSK9 amplified platelet activation by ox-LDL pathway we performed platelet aggregation in wPLT
incubated with and without LDL (50 µg/mL). To evaluate PA in wPLT we added, immediately before
to induce aggregation, CaCl2 and fibrinogen (1 mM and 100 µg/mL, respectively; Sigma Aldrich,
St. Louis, MO, USA). Finally, all samples were centrifuged for 3 min at 3000 rpm and supernatants
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and pellets were separated and stored at –80 ◦C for analysis of sNox2-dp, H2O2, isoprostanes, TXB2,
ox-LDL, conjugated dienes and p38, p47 and PLA2 phosphorylation, as reported below.
2.3. Serum and Platelet sNox2-dp
Serum and platelet Nox2 were measured as a soluble Nox2-derived peptide (sNox2-dp) with an
ELISA method as previously reported [13]. Briefly, the peptide is recognized by binding to a specific
monoclonal antibody against the amino acid sequence (224–268) that corresponds to the extracellular
membrane part of Nox2 (catalytic core of NADPH oxidase), which was released following platelet
activation. The enzyme activity is measured spectrophotometrically by the increased absorbance at
450 nm. Values were expressed as pg/mL; intra-assay and inter-assay coefficients of variation were
8.95% and 9.01%, respectively.
2.4. Serum and Platelet H2O2 Production
The Hydrogen Peroxide (H2O2) was measured by using a colorimetric assay as described
previously [14]. A standard curve of H2O2 (0–200 µM) was performed for each assay. In brief, samples
were mixed with colorless colorimetric substrate (50 µL of 3,3′,5,5′-tetramethylbenzidine in 0.42 mol/L
citrate buffer, pH 3.8) and and the reaction initiated by addition of horseradish peroxidase (HRP,
52.5 U/mL). After, the samples were incubated at room temperature for 20 min, and the reaction was
stopped adding an acid solution (18 N sulphuric acid). The product was read at 450 nm and expressed
as µM. Intra-assay and inter-assay coefficients of variation were both < 10%.
2.5. Platelet and Urinary 8-Iso-PGF2α Assay
Platelet and urinary isoprostanes (8-iso-PGF2α) were measured by the enzyme immunoassay
technology (DRG Inter-national, Springfield, NJ, USA) the values were expressed in pmol/L and
pg/mg creatinine, respectively. Intra-assay and inter-assay coefficients of variation were 5.8% and
5.0%, respectively.
2.6. Serum Detection of Oxidization of Low-Density Lipoprotein (ox-LDL)
ox-LDL were measured by commercially available immunoassays (Cusabio, Houston, TX, USA).
The optical density of samples was read at 450 nm and were expressed in mU/L. Intra-assay and
inter-assay coefficients of variation were < 8% and < 10%, respectively.
2.7. Serum and Platelet TxB2 Assay
Serum and platelet TxA2 were analyzed by estimating its stable metabolite named TxB2 in the
supernatant by an ELISA commercial kit (Cusabio, Houston, TX, USA), according to manufacturer
instructions. The values were expressed as pg/mL × 108 cells and pg/mL, respectively. Intra- and
inter-assay coefficients of variation for TxB2 were < 8% and < 10%, respectively.
2.8. Serum and Platelet sP-selectin Assay
Serum and platelet sP-selectin concentrations were evaluated by a commercial immunoassay kit
(Diaclone), and values were expressed as ng/mL; intra- and inter- assay coefficients of variation were
5.6% and 7.5%, respectively.
2.9. LDL Isolation and Determination of Conjugated Dienes
Human LDL was obtained from healthy subjects and blood was collected into tubes with 7.2 mg
EDTA. Briefly, (1) blood was centrifuged at 1500× g for 10 min at 4 ◦C, (2) 250 µL of PBS adding
0.25 mM EDTA was used to stratified 750 µL of plasma, (3) tubes were centrifuged at 100,000 rpm
for 7 min, (4) the upper 250 µL was removed to eliminate chylomicrons and (5) 250 µL of PBS with
0.25 mM EDTA was added again; (6) samples were centrifuged at 100,000 rpm for 2.5 h; (7) next, 250 µL
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of the upper layer was eliminated and (8) 150 µL of potassium bromide (KBr) (50%, w/v) was added,
the final density obtained is 1.063 g/mL. Samples were centrifuged at 100,000 rpm for 5 h and and the
fraction containing LDL was recovered. Finally, 200 µL of the fraction of LDL was dialyzed with PBS
containing EDTA.
LDLs were oxidized by copper sulfate (CuSO4) and the degree of oxidation was evaluated
by conjugated dienes formation using a UV/VIS spectrometer (PerkinElmer, Waltham, MA, USA).
Measurement of the 234 nm absorption was read in the cell supernatant after oxidation and expressed
as µg/mL of conjugated dienes [15].
2.10. Co-Immunoprecipitation Assays and Western Blot Analysis
For co-immunoprecipitation (IP), platelet pellets were suspended in RIPA buffer with protease
and phosphatase inhibitors cocktail (10 µg/mL; Thermo Fisher Scientific, MA, USA) and sonicated
three times (for 10 s and 70% amplitude). Once the samples were sonicated, they were incubated on ice
for 30 min. After this, the samples were centrifuged at 10,000× g for 20 min to remove pellet residues
(residues may contain unlysed cells, nuclei or unlysed organelles) and the supernatants were collected.
The protein concentration of each lysate was determined by Bradford assay.
Cellular proteins (500 µg) were diluted in RIPA buffer and incubated with corresponding mouse
monoclonal antibodies anti-CD36 or anti-LOX-1 (1 µg/mg protein) overnight at 4 ◦C. Then protein-A/G
agarose (Santa Cruz Biotechnology, Dallas, TX, USA) was added to the mixtures and adequately
resuspended. After incubation for 60 min at 4 ◦C, the mixtures were centrifuged at 2500 rpm for 5 min
and pellet washed with RIPA buffer 3 times. Finally, the immunoprecipitates were dissolved in a mix
solution consisting of (lysis buffer with 4X Leammli sample buffer and 20% of 2-mercaptoethanol)
(Bio-Rad, Hercules, CA, USA) and heated at 100 ◦C for 5 min. Proteins were resolved by SDS-PAGE
on 7% polyacrylamide gel and transferred on nitrocellulose membranes. After blocking with BSA
(5%), membranes were incubated with anti-PCSK9, (Santa Cruz Biotechnology, Dallas, TX, USA) and
incubated overnight at 4 ◦C.
To analyse p38, p47phox and PLA2 phosphorylation we used the same procedure but immediately
after cell lysis, 30 µg/lane were separated by SDS-PAGE on 10–12% polyacrylamide gel. Moreover,
membranes were incubated overnight at 4 ◦C with rabbit polyclonal anti-p-p47phox (1:1000; ab-795,
Abcam, Cambridge, UK), anti-p-p38 and anti-p-cPLA2 antibody (1:1000; sc-7973 and sc34392, Santa
Cruz Biotechnology, Dallas, TX, USA; respectively), and anti-p47phox, anti-p38 and anti-cPLA2
antibody (1:1000; sc-17845, sc-7973 and sc-376618, Santa Cruz Biotechnology, TX, USA; respectively).
Then, the membranes were incubated for 1 h with HRP-conjugated secondary antibody (1:3000;
Bio-Rad, Hercules, CA, USA) and the co-immune and immune complexes were detected by enhanced
chemiluminescence substrate (ECL Substrates, Bio-Rad, Hercules, CA, USA). Densitometric analysis of
the bands was performed using Image J software v6.0.1 (BioRad, Hercules, CA, USA). The results were
expressed as arbitrary units (A.U.) and represent the mean of three independent experiments.
2.11. Statistical Analysis
For analysis, all data were expressed as means ± SEM. Statistical comparisons were performed
using one-way ANOVA or Student t test and p values < 0.05 were considered to be statistically significant.
All tests were performed using GraphPad Software-Prism7 (GraphPad Company, San Diego, CA,
USA).
3. Results
3.1. Ex-Vivo Study
Clinical characteristics of AF patients enrolled for the study are summarized in Table 1.
Median values of PCSK9 in the entire population was 1.2 ng/mL, 44 having above and 44
below 1.2 ng/mL levels. Compared to patients with PCSK9 < 1.2 ng/mL, patients with plasma
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levels of PCSK9 > 1.2 ng/mL, displayed higher platelet aggregation, (49.8 ± 2.5% vs. 68.6 ± 1.9%;
**p < 0.001) (Figure 1A), platelet recruitment (16.46± 1.568% vs. 31.20± 1.861%; **p < 0.001) (Figure 1B),
sP-selectin (7.7 ± 0.6 ng/mL vs. 14.7 ± 0.45 ng/mL; **p < 0.001) (Figure 1C) and serum levels of TxB2
(121.5 ± 1.9 pg/mL vs. 245.5 ± 4.6 pg/mL; **p < 0.001) (Figure 1D).
Figure 1. Proprotein convertase subtilisin/kexin 9PCSK9 and platelet activation in atrial fibrillation
(AF) patients. Platelet aggregation (A), platelet recruitment (B), plasma soluble P-selectin (sP-selectin)
(C) and serum TxB2 (D) in 44 AF patients with plasma levels of PCSK9 < 1.2 ng/mL and 44 AF patients
with plasma levels of PCSK9 > 1.2 ng/mL. (Data are represented as median and IQR. ** p < 0.001).
Moreover, compared to patients with PCSK9 < 1.2 ng/mL, patients with PCSK9 >1.2 ng/mL
displayed an increased levels of markers of oxidative stress such as s-Nox2dp (21.4 ± 0.9 pg/mL vs.
34.4 ± 1,1 pg/mL; **p < 0.0001) (Figure 2A), H2O2 (29.5 ± 1.3 µM vs. 48.8 ± 1.6 µM; **p < 0.001)
(Figure 2B), ox-LDL (12.0 ± 0.9 mU/mL vs. 33.5 ± 1.1 mU/mL; **p < 0.001) (Figure 2C) and 8-iso-PGF2α
(137.2 ± 22.0 pg/mg creatinine vs. 272.0 ± 8.6 pg/mg creatinine; **p < 0.001) (Figure 2D), respectively.
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Figure 2. PCSK9 and oxidative stress in AF patients. Nox2 activation (A), H2O2 production (B),
ox-LDL formation (C) and 8-iso-PGF2α (D) biosynthesis in 44 AF patients with plasma levels of PCSK9
< 1.2 ng/mL and 44 AF patients with plasma levels of PCSK9 > 1.2 ng/mL. (Data are represented as
median and IQR. **p < 0.001).
Circulating levels of PCSK9 are significantly positively associated with markers of platelet
activation and oxidative stress (Table 2).
Table 2. Correlation between markers of platelet activation and oxidative stress and PCSK9 levels.
PCSK9
Rs p-value
Platelet Aggregation 0.309 <0.001
Platelet Recruitment 0.485 <0.001
sP-selectin 0.330 <0.001
Serum TxB2 production 0.538 <0.001
Serum sNox2-dp 0.314 <0.001
Hydrogen peroxide 0.185 <0.001
Urinary 8-iso-PGE2α 0.336 <0.001
Ox-LDL production 0.550 <0.001
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3.2. In Vitro Study
3.2.1. PCSK9 and Platelet Activation
Platelets co-incubated with PCSK9 and stimulated with STC collagen showed a dose-dependent
increase of platelet aggregation and TxB2 biosynthesis compared to STC collagen platelets alone
(Figure 3A–C). Such an effect was inhibited by the addition of anti-CD36, Nox2ds-tat and anti-PCSK9
(Figure 3A–C). No significant changes were observed with anti-LOX1 (Figure 3A–C). Finally, platelet
incubation with inhibitors alone, without PCSK9 did not show significant variations, neither in platelet
aggregation nor in TxB2 biosynthesis (Figure S1A–C).
Figure 3. PCSK9 and platelet activation. Platelet aggregation (A) with relative representative tracing
(B) and platelet TxB2 (C) evaluated in platelet rich plasma (PRP) treated with PCSK9 (1 and 2 ng/mL)
and stimulated with subthreshold concentration (STC) of collagen (0.25 µg/mL) in presence or not of
anti-CD36, anti-LOX1, Nox2ds-tat and anti-PCSK9. (n = 5) (*p < 0.05, **p < 0.001 for paired analyses).
3.2.2. PCSK9 and Oxidative Stress
Similarly, platelets co-incubated with PCSK9 and stimulated with STC collagen showed a
dose-dependent increase of Nox2 activation, H2O2 production, isoprostanes biosynthesis and ox-LDL
formation compared to STC collagen platelets alone (Figure 4A–D). Such effect was inhibited by
anti-CD36, Nox2ds-tat and anti-PCSK9 (Figure 4A,B). No significant changes were observed with
anti-LOX1 (Figure 4A,B).
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Figure 4. PCSK9 and oxidative stress. Nox2 activation (A), H2O2 production (B), 8-iso-PGF2α-III (C)
and ox-LDL formation (D) evaluated in PRP treated with PCSK9 (1 and 2 ng/mL) and stimulated with
STC of collagen (0.25 µg/mL) in presence or less of anti-CD36, anti-LOX1, Nox2ds-tat and anti-PCSK9.
(n = 5) (**p < 0.001 for paired analyses).
3.2.3. Intra-Signalling Pathway of Platelet Activation PCSK9-Mediated p38MAP Kinase, p47phox and
cPLA2 Phosphorylation
To analyse the pathway involved in PCSK9-dependent platelet activation by ROS, we studied
p47phox translocation on the platelet membrane, the role of p38MAP kinase, which is implicated in
p47phox activation [16] as final and key event upstream of Nox2 activation, and cPLA2 phosphorylation,
a key enzyme for generation of eicosanoids. STC collagen-stimulated platelets in the presence of PCSK9
(2 ng/mL) showed a significant increase in p38MAP kinase, p47phox and cPLA2 phosphorylation
compared to STC collagen platelets alone (Figure 5A–C); this effect was inhibited in platelets
pre-incubated with anti-CD36, anti-PCSK9, p38 inhibitor, Nox2ds-tat and AACOCF3 (Figure 5A–C).
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Figure 5. Intra-signalling pathway of platelet activation PCSK9-mediated: p38MAP Kinase, p47phox and
PLA2 phosphorylation. p38 phosphorylation, p47phox phosphorylation and cPLA2 phosphorylation
was analysed in platelets incubated with PCSK9 (1–2 ng/mL) and stimulated with subthreshold
concentration (STC) of collagen (0.25 µg/mL) (A–C) in presence or less of anti-CD36, anti-LOX1,
anti-PCSK9 (A–C) and incubated with or without SB (A), Nox2ds-tat (B) and AACOCF3 (C) (n = 3
independent experiments; *p < 0.05 **p < 0.001 in quantitative analysis). A representative Western blot
of p38, p47phox and cPLA2 phosphorylation (B–C).
3.2.4. PCSK9 and LDL-Mediated Platelet Activation
No significant changes in platelet activation parameters were detected in STC collagen-stimulated
washed platelets in the presence of PCSK9 (1 ng/mL) compared to STC collagen-stimulated platelets
alone (Figure 6A–C). Conversely, STC collagen-stimulated washed platelets in the presence of
PCSK9 (2 ng/mL) showed an increase of platelet aggregation and TxB2 formation compared to
STC collagen-stimulated platelets alone (Figure 6A–C). Of note, when PCSK9-treated platelets were
also added LDL (50 µg/mL) a further increase in PA was detected, an effect blunted by CD36 or Nox2
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inhibitors (Figure 6A–C). Finally, a significant increase in conjugated dienes formation was detected in
STC collagen-stimulated washed platelets in the presence of PCSK9 (2 ng/mL) and LDL compared to
STC collagen-stimulated platelets incubated with LDL alone (Figure 6D); PCSK9-induced formation of
conjugated dienes was inhibited by CD36 or Nox2 inhibitors.
Figure 6. PCSK9 and platelet activation LDL-mediated. Platelet aggregation (A) with relative
representative tracing (B), TxB2 production (C) and conjugated dienes formation (D) evaluated in
washed platelet treated with PCSK9 alone (1–2 ng/mL) and stimulated with subthreshold concentration
(STC) of collagen (0.25 µg/mL) in presence or less of exogenous LDL (50 µg/mL), Nox2ds-tat and
anti-CD36. (n = 5; *p < 0.05, **p < 0.001 for paired analyses).
3.2.5. PCSK9 Activates Platelets by CD36 Signalling
We investigated if PCSK9 directly interacts with CD36 and LOX-1, two major receptors for ox-LDL
on platelets surface [17,18], by assessing a co-immunoprecipitation between PCSK9 and CD36 or LOX1.
As reported in Figure 7, we demonstrated that PCSK9 co-immunoprecipitated with CD36 but not with
LOX1. (Figure 7A,B).
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Figure 7. PCSK9 activates platelets by CD36 signalling. Densitometric analysis of Western blotting
(WB) showing coimmunoprecipitation of CD36 and LOX1 with PCSK9 in human platelets stimulated
with PCSK9 2 ng/mL (A). A representative Western blot bands of immune complexes CD36-PCSK9 and
LOX1-PCSK9, the lane with 10% of the extract loaded before of IP (input) are shown (B). Results are
representative of three independent experiments.
4. Discussion
This study provides evidence that high circulating levels of PCSK9 are associated with increased
platelet activation with a mechanism involving CD36 and eventually Nox2 activation. Such interaction
is amplified in the presence of LDL. A direct link between PCSK9 levels and markers of platelet activity
such as urinary TxB2 was observed in patients affected by AF [4] but the role of platelets was unclear
also because it is still undefined as to whether platelet activation contributes to urinary TxB2 [19].
Hence, a definite association between PCSK9 levels and platelet reactivity is still lacking.
In our study, we analysed platelet function and ROS profiles comparing AF patients according to
median PCSK9, i.e., 1.2 ng/mL, which is able to discriminate patients at an increased risk of CVEs [4].
We found that the population with PCSK9 levels > 1.2 ng/mL presented a significantly higher rate
of platelet aggregation and recruitment coincidentally with higher levels of serum TxB2 formation,
P-selectin release, ROS and ox-LDL. This finding was corroborated by in vitro study showing that
2 ng/mL PSCK9 was able to amplify the platelet response to collagen.
To investigate the underlying mechanism, we focused on down-stream pathways involving
ROS-derived NADPH oxidase as this enzymatic pathway is activated by PCSK9 mediated increased
cell activity in other models such as endothelial and smooth muscle cells [2].
A novelty of the present study is the demonstration that PA amplification by PCSK9 was associated
with Nox2 activation suggesting a ROS-mediated pathway. Accordingly, PCSK9-mediated PA was
associated with both p47phox and cPLA2 phosphorylation, which explains on one hand 8-iso-PGF2α
over-production and on the other hand the enhanced TxA2 biosynthesis.
Recent data showed that in patients with familiar hypercholesterolemia anti-PCSK9 mAb treatment
inhibits platelet reactivity but it is unclear if this effect is mediated by a direct interaction between
PCSK9 and platelets or by LDL lowering [6]. Our data suggest that both contribute to platelet activation
as in washed platelets PCSK9 per se behaves as a platelet agonist, an effect, however, that is amplified if
PCSK9 is co-incubated with LDL. Such amplification by LDL was dependent on an enhanced formation
of ox-LDL, a phenomenon already shown to amplify the platelet response to other agonists [15].
Finally, we demonstrated, by a co-immunoprecipitation method, that PCSK9 binds CD36 receptor
so indicating that it activates aggregation by directly binding platelets. The down-stream signalling
elicits platelet aggregation including ROS-derived Nox2 activation [9]. Taken together these data lead
us, therefore, to hypothesize that the inhibition of platelet activation by PCSK9 mAb may occur via at
least two mechanisms, one involving down-regulation of PCSK9 and the other LDL lowering.
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This study has limitations and implications. The current data should be considered with caution
as data were derived from an observational study and should be confirmed by an interventional study
with a PCSK9 inhibitor drug. Moreover the direct interaction between PCSK9 and the platelet CD36
receptor should be better investigated by confocal immunofuorescence microscopy as reported by
Demers and collaborators [20].
The fact that PCSK9 behaves as platelet agonist suggests that the beneficial effects of PCSK9 mAb
may be dependent not only on LDL lowering but also by the inhibition of platelet function. This
hypothesis, however, needs to be validated by an appropriate interventional study.
5. Conclusions
In conclusion, we demonstrated for the first time that PCSK9, at a concentration commonly
found in the human circulation of AF patients, directly induces CD36-mediated platelet activation by
amplifying Nox2 activity: this effect is amplified in the presence of LDL (Graphical Abstract).
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analyses).
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